Key Points
- Leah Spasova, a psychologist from Oxfordshire, won her complaint after a 10-year struggle to obtain female sterilisation on the NHS.
- The Parliamentary and Health Service Ombudsman found that the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board treated women unfairly by refusing funding for sterilisation while routinely funding vasectomies for men.
- The refusal was linked to concerns about possible regret and cost-effectiveness, reasons the ombudsman said were not applied in the same way to men seeking vasectomies.
- The ombudsman described the ICB’s approach as unfair, inconsistent and based on subjective reasoning.
- Paula Sussex, the Parliamentary and Health Service Ombudsman, said the case showed the power of the patient voice and that the ICB is now reviewing its sterilisation policy.
- Thames Valley ICB said it has introduced a new policy so eligible patients can access female sterilisation.
- The case has reignited debate over bodily autonomy, equal access to permanent contraception and whether women face stricter controls than men in the NHS.
Oxford (Britain Today News) May 2, 2026 – British woman Leah Spasova has won a major complaint after the health ombudsman ruled that an NHS body treated women unfairly by denying funding for sterilisation while funding vasectomies for men, ending a fight that lasted 10 years.
What happened in the case?
Leah Spasova was denied permanent birth control through the NHS because officials said she might regret the decision, but the same reasoning was not used to refuse vasectomies for men. The complaint centred on the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board, which covers part of southern England.
Spasova, who is based in Oxfordshire, said she had been asking about sterilisation for years and felt she was passed from one service to another without a clear decision. She eventually challenged the decision through the Parliamentary and Health Service Ombudsman, which investigates complaints about the NHS in England.
The ombudsman sided with her and found that the local health body was not applying the same standards to women and men. In simple terms, the board was treating female sterilisation as something requiring extra suspicion, while male sterilisation was more readily supported.
Why did the ombudsman criticise the NHS body?
The core issue was not only access, but fairness. The ombudsman found that the ICB did not routinely fund female sterilisation and relied on concerns about cost and possible regret to deny women the procedure. Those same barriers were not used in the same way for men requesting vasectomies.
That difference mattered because the health service is expected to apply decisions consistently and to respect patients’ ability to make informed choices about their own bodies. Spasova said her research suggested the ICB had not followed the principle that clinicians advise, while patients decide.
The ombudsman concluded the board’s handling of the case was unfair, inconsistent and based on subjective reasoning. It also found women were not being given the same opportunity as men to make an informed decision about sterilisation.
What did Leah Spasova say?
Spasova said she had been enquiring about sterilisation for a decade and kept being
“passed back and forth between services”.
She said the ICB’s refusal was especially frustrating because it appeared to put the burden of imagined regret onto her, rather than respecting her decision as an adult patient.
She also described the policy as discriminatory and said the wider problem of unequal access to permanent contraception remained unresolved. Her case has now become a symbolic example of a wider complaint many women have raised about unequal treatment in reproductive healthcare.
The language used in the complaint matters because it goes beyond one refusal and points to a system-level problem. In Spasova’s view, the refusal was not just inconvenient, but a denial of bodily autonomy.
How did the ombudsman respond?
Paula Sussex, the Parliamentary and Health Service Ombudsman, said the case demonstrated the importance of patients speaking up when they believe care has fallen short. She said Leah’s complaint had prompted the ICB to review its sterilisation policy.
The ombudsman also suggested there may be wider issues across the NHS beyond this single complaint. That point is important because it implies the problem could affect more women in more than one area if similar policies are being used elsewhere.
In addition, the ombudsman recommended that the ICB write to Spasova to acknowledge its failings. That is a formal recognition that the original decision did not meet the standard expected of a public health body.
What has the NHS body changed?
Following the complaint, the committee responsible for policy recommendations for six ICBs in the south-east reviewed the female sterilisation policy. It proposed that female sterilisation should be funded and that regret or the existence of alternative contraception should no longer be valid reasons to refuse access.
Thames Valley ICB, which now oversees health services in the area, said it has introduced a new policy to ensure eligible patients can access female sterilisation. It also said it is redesigning its complaints process so that concerns about local services can be handled more effectively and more quickly.
That change is significant because it shows the complaint did not only produce criticism, but also a policy response. However, the broader debate over whether women still face higher barriers than men remains very much alive.
Why does this case matter?
The case highlights a long-running issue in reproductive healthcare: women often face more scrutiny when seeking permanent contraception than men do. Supporters of reform argue that if vasectomies are funded on the NHS, female sterilisation should not be blocked by assumptions about regret that are not equally applied to men.
Female sterilisation is a permanent procedure that blocks the fallopian tubes, while vasectomy is the male equivalent and is generally less invasive. That difference in medical process does not, by itself, justify unequal treatment in access decisions, which is why the ombudsman’s findings have drawn attention.
The case also touches on a wider ethical question: who gets the final say over reproduction and contraception. For Spasova, the issue was always about autonomy, dignity and equal treatment rather than a single form being denied.
What happens next?
The immediate practical result is that the local ICB has changed its policy and says eligible patients can now access female sterilisation. The ombudsman’s criticism may also encourage other NHS bodies to examine whether they apply different rules to men and women.
For patients, the case may offer a stronger basis to challenge refusals that appear to rely on subjective assumptions rather than clear medical criteria. For the NHS, it is a reminder that equal access and consistent decision-making are not optional extras, but core public service expectations.
